PE20060160A1 - Formulaciones de tableta recubierta que comprenden peliglitazar o muraglitazar y procedimiento - Google Patents

Formulaciones de tableta recubierta que comprenden peliglitazar o muraglitazar y procedimiento

Info

Publication number
PE20060160A1
PE20060160A1 PE2005000343A PE2005000343A PE20060160A1 PE 20060160 A1 PE20060160 A1 PE 20060160A1 PE 2005000343 A PE2005000343 A PE 2005000343A PE 2005000343 A PE2005000343 A PE 2005000343A PE 20060160 A1 PE20060160 A1 PE 20060160A1
Authority
PE
Peru
Prior art keywords
coating
coated tablet
peliglitazar
muraglitazar
layer
Prior art date
Application number
PE2005000343A
Other languages
English (en)
Inventor
Divyakant S Desai
Danping Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060160A1 publication Critical patent/PE20060160A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE TABLETA RECUBIERTA QUE INCLUYE UN AGENTE CON ACTIVIDAD AGONISTA DE PPAR */* COMO PELIGLITAZAR O MURAGLITAZAR. ESTA TABLETA RECUBIERTA ESTA COMPRENDIDA POR a) UN NUCLEO FORMADO POR UNO O MAS AGENTES RELLENADORES, AGLUTINANTES, DESINTEGRANTES Y OTROS EXCIPIENTES CONVENCIONALES Y OPCIONALMENTE PUEDE COMPRENDER EL AGENTE ACTIVO; Y b) AL MENOS UNA CAPA DE RECUBRIMIENTO CONSTITUIDO POR UNO O MAS AGENTES ACTIVOS Y EL POLIMERO DE RECUBRIMIENTO, SIENDO PREFERIDO UN POLIMERO A BASE DE HIDROXIPROPILMETIL CELULOSA, TAL CAPA ES APLICADA PREFERENTEMENTE POR RECUBRIMIENTO POR ROCIADO SOBRE EL NUCLEO DE LA TABLETA; Y c) OPCIONALMENTE UNA SEGUNDA CAPA DE RECUBRIMIENTO COLOCADA SOBRE LA CAPA ANTERIOR DE SEMEJANTE COMPOSICION A LA CAPA DE RECUBRIMINIENTO INICIAL, EXCEPTO QUE NO INCLUYE EL AGENTE ACTIVO. TAMBIEN SE REFIERE A UN PROCESO PARA FORMAR LA TABLETA RECUBIERTA POR MEDIO DE UNA TECNICA DE RECUBRIMIENTO CON SECADO POR ROCIADO
PE2005000343A 2004-03-25 2005-03-28 Formulaciones de tableta recubierta que comprenden peliglitazar o muraglitazar y procedimiento PE20060160A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55633104P 2004-03-25 2004-03-25
US64887205P 2005-02-01 2005-02-01

Publications (1)

Publication Number Publication Date
PE20060160A1 true PE20060160A1 (es) 2006-03-15

Family

ID=35064439

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000343A PE20060160A1 (es) 2004-03-25 2005-03-28 Formulaciones de tableta recubierta que comprenden peliglitazar o muraglitazar y procedimiento

Country Status (13)

Country Link
US (1) US20050214373A1 (es)
EP (1) EP1734921A2 (es)
JP (1) JP2007530565A (es)
KR (1) KR20060128028A (es)
AR (1) AR048332A1 (es)
AU (1) AU2005228988A1 (es)
BR (1) BRPI0509194A (es)
CA (1) CA2560812A1 (es)
MX (1) MXPA06010775A (es)
PE (1) PE20060160A1 (es)
RU (1) RU2006137672A (es)
TW (1) TW200534879A (es)
WO (1) WO2005094786A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
SI2170292T1 (sl) * 2007-06-22 2014-05-30 Bristol-Myers Squibb Holdings Ireland Tabletirani sestavki, ki vsebujejo atazanavir
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
JP2010530892A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
ES2359770T3 (es) * 2007-06-22 2011-05-26 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
MY171941A (en) 2010-11-24 2019-11-08 Melinta Subsidiary Corp Pharmaceutical compositions
JP6231553B2 (ja) 2012-05-07 2017-11-15 バイエル ファーマ アクチエンゲゼルシャフト ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
CA2368023A1 (en) * 1999-03-22 2000-09-28 Guixue Yu Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001034148A1 (en) * 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
WO2002085335A1 (en) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
KR20060128028A (ko) 2006-12-13
TW200534879A (en) 2005-11-01
JP2007530565A (ja) 2007-11-01
CA2560812A1 (en) 2005-10-13
EP1734921A2 (en) 2006-12-27
RU2006137672A (ru) 2008-04-27
AR048332A1 (es) 2006-04-19
AU2005228988A1 (en) 2005-10-13
MXPA06010775A (es) 2006-12-15
US20050214373A1 (en) 2005-09-29
BRPI0509194A (pt) 2007-08-28
WO2005094786A3 (en) 2006-05-04
WO2005094786A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
MX2018016056A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
UA91376C2 (ru) Рецептура с контролируемым высвобождением
AR052186A1 (es) Composiciones de recubrimiento acuosas
CL2008002720A1 (es) Composicion farmaceutica transdermica para nebulizar, sin alcohol, que comprende uno o mas farmacos, los potenciadores de la penetracion transdermica eteres de dietilenglicol o filtros solares de ester, y liquidos no volatiles; dispositivo de dosificacion de nebulizacion medida que la comprende; metodo de fabricacion; y su uso.
EP2231761A4 (en) QUATERNARY AMMONIUM POLYMERS DISINFECTANTS SOLUBLE IN ALCOHOL
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
CO6501159A2 (es) Formulaciones farmaceuticas de liberación controlada de nitazoxanida
EA200702198A1 (ru) Фармацевтические составы
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
AR051128A1 (es) Composiciones encapsuladas para activos, termicamente estables, altamente resistentes
AR048332A1 (es) Formulaciones de tableta recubierta y metodo
BRPI0614545B8 (pt) composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma
AR055123A1 (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica
PT1355635E (pt) Novo revestimento de pelicula
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
ATE286736T1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
BRPI0412458A (pt) composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).

Legal Events

Date Code Title Description
FD Application declared void or lapsed